Loading...
TPTX logo

Turning Point Therapeutics, Inc.NasdaqGS:TPTX Stock Report

Market Cap US$3.8b
Share Price
n/a
1Y18.9%
7D1.3%
1D0.7%
Portfolio Value
​
View

Turning Point Therapeutics, Inc.

NasdaqGS:TPTX Stock Report

Market Cap: US$3.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Turning Point Therapeutics (TPTX) Stock Overview

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. More details

TPTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 73.92% per year

Risk Analysis

Highly volatile share price over the past 3 months

Does not have meaningful revenue ($1M)

Currently unprofitable and not forecast to become profitable over the next 3 years


TPTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,106 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
499,106 investors already sharing narratives
View all narratives

Turning Point Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Turning Point Therapeutics
Historical stock prices
Current Share PriceUS$76.01
52 Week HighUS$82.20
52 Week LowUS$23.77
Beta-0.19
1 Month Change1.58%
3 Month Change114.96%
1 Year Change18.90%
3 Year Change45.39%
5 Year Changen/a
Change since IPO163.01%

Recent News & Updates

Recent updates

Seeking Alpha • Jul 21

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Bristol Myers  Squibb (NYSE:BMY) is reportedly expected to make antitrust filings to U.S. and German authorities "imminently" for its planned $4.1 billion purchase of Turning Point Therapeutics (NASDAQ:TPTX), according to a Dealreporter item. The acquisition remains on track for a Q3 closing, according to the report, which cited sources familiar. The deal update comes after BMY on Tuesday extended the tender offer for its acquisition of Turning Point Therapeutics (TPTX) to Aug. 15. BMY agreed to acquire the clinical-stage precision oncology biotech Turning Point (TPTX) at a price of $76.00 per share in cash for a total consideration of $4.1B early last month.
Analysis Article • Mar 23

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 06

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 03

The Take On Turning Point Therapeutics

After peaking at over $141 in February 2021, shares of Turning Point Therapeutics, Inc. had lost 55% of their value through early October, largely due to a data vacuum. That silence was broken on October 7, 2021, with solid, yet short-of-expectations results for its lead candidate (repotrectinib) in a second-line or later setting for ROS1+ NSCLC. The Street is still awaiting pivotal additional data for repotrectinib in a frontline setting, where initial data indicated a 90+% ORR for ROS1+ NSCLC. With a potentially best-in-class therapy and $1 billion in cash, this precision oncology firm merited a deeper dive. A full analysis follows in the paragraphs below.
Analysis Article • Aug 15

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Celebrations may be in order for Turning Point Therapeutics, Inc. ( NASDAQ:TPTX ) shareholders, with the analysts...
Analysis Article • Aug 04

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • May 08

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

It's been a mediocre week for Turning Point Therapeutics, Inc. ( NASDAQ:TPTX ) shareholders, with the stock dropping...
Analysis Article • Feb 26

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Analysis Article • Jan 22

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Celebrations may be in order for Turning Point Therapeutics, Inc. ( NASDAQ:TPTX ) shareholders, with the analysts...
Analysis Article • Jan 13

We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, Turning Point...
Analysis Article • Dec 15

Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Today we will run through one way of estimating the intrinsic value of Turning Point Therapeutics, Inc. ( NASDAQ:TPTX...

Shareholder Returns

TPTXUS BiotechsUS Market
7D1.3%2.3%0.8%
1Y18.9%42.3%20.2%

Return vs Industry: TPTX exceeded the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: TPTX exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is TPTX's price volatile compared to industry and market?
TPTX volatility
TPTX Average Weekly Movement34.2%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: TPTX's share price has been volatile over the past 3 months.

Volatility Over Time: TPTX's weekly volatility has increased from 20% to 34% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013267Athena Countouriotiswww.tptherapeutics.com

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company’s lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors.

Turning Point Therapeutics, Inc. Fundamentals Summary

How do Turning Point Therapeutics's earnings and revenue compare to its market cap?
TPTX fundamental statistics
Market capUS$3.81b
Earnings (TTM)-US$342.31m
Revenue (TTM)US$1.01m
3,776x
P/S Ratio
-11.1x
P/E Ratio

Is TPTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TPTX income statement (TTM)
RevenueUS$1.01m
Cost of RevenueUS$0
Gross ProfitUS$1.01m
Other ExpensesUS$343.32m
Earnings-US$342.31m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-6.84
Gross Margin100.00%
Net Profit Margin-33,959.03%
Debt/Equity Ratio0%

How did TPTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/08/17 04:31
End of Day Share Price 2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Turning Point Therapeutics, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Arlinda LeeCanaccord Genuity
Silvan TuerkcanCitizens JMP Securities, LLC